U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06926842) titled 'Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)' on April 11.
Brief Summary: The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Study Start Date: April 21
Study Type: INTERVENTIONAL
Condition:
Overweight
Type 2 Diabetes
Obesity
Intervention:
DRUG: Petrelintide
Petrelintide will be taken by participants once weekly subcutaneously.
OTHER: Placebo
Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
...